Placebo for Enlicitide

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HypercholesterolemiaHyperlipidemia

Phase 3

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

CompletedNCT06450366

Merck Sharp & Dohme LLCHypercholesterolemia

Start: 2024-07-08End: 2025-03-28Updated: 2026-03-27

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

RecruitingNCT07216482

Merck Sharp & Dohme LLCHyperlipidemia

Start: 2025-11-11End: 2027-03-01Target: 975Updated: 2026-04-01